PDS Biotechnology — Third Quarter 2026 Earnings Summary

PDS Biotechnology Corporation reported a net loss of $7.6 million, or $0.11 per share, for the third quarter ended September 30, 2026, compared to a $9.0 million loss in the same period the previous year. The company announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC, which included the appointment of Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. During the quarter, research and development expenses decreased to $2.1 million from $4.6 million in the prior year period, primarily due to reduced clinical trial costs. As of September 30, 2026, the company held $15.2 million in cash and cash equivalents while continuing to prioritize its lead program, PDS0301, and advancing its Versamune cancer vaccine platform.